
Zealand Pharma reports up to 9.2% weight loss in Phase 2 diabetes trial
The 220-person ZUPREME-2 trial also showed improved HbA1c; Zealand says the first participants have begun treatment in its Phase 3a program.

The 220-person ZUPREME-2 trial also showed improved HbA1c; Zealand says the first participants have begun treatment in its Phase 3a program.

Nine-month test deliveries more than doubled, while third-quarter CyPath revenue awaits formal results.

PharmaLogic supplied doses to hospitals in Indiana and Ohio; Telix's Oct. 6 launch release gave no Pixclara sales target.



A 37.1-minute placebo-adjusted shift in sleep onset supports Vanda's plan to seek a third U.S. HETLIOZ indication.
ECG-MR is cleared to flag possible valve disease in at-risk patients 65 and older, while Tempus's Sept. 28 release gave no rollout date.
First U.S. approval covers peripheral thyrotoxicosis in MCT8 deficiency; Egetis expects commercial availability eight to 10 weeks after Sept. 28.
The Sept. 25 adult Parkinson's approval clears one condition for a payment-rights purchase expected to close Sept. 29.
A September QIAGEN safety document lists 13 bacterial targets and 18 resistance markers for the newly cleared assay.
FDA cleared the weekly basal insulin for adults with type 2 diabetes on Sept. 24; Lilly expects the U.S. pen in the coming months.
The application seeks dosing for smaller children with APDS, and the FDA set Jan. 30, 2027 as its target action date.
Mirum expects U.S. availability in October after a 63-patient study; its prespecified new-lesion incidence endpoint missed the conventional threshold.
In the 257-person pivotal cohort, 42 per cent on 4 mg reached the scalp hair endpoint at Week 36, against 5 per cent on placebo.
The TIBA test joins two existing checks on new commercial lots as Mesoblast scales U.S. sales of its pediatric cell therapy.
Researchers trained the underlying models using billions of minutes of sensor data from users who joined its research programs
It is nearly as accurate as a mass spectrometer
If you can avoid spraying yourself with a toxic chemical, you probably should
The system also integrates endobronchial ultrasound to examine nearby lymph nodes
She held a book signing for 'One Scan Saved My Life' this week
It aims to identify an optimal dosing regimen for patients that minimizes anxiety
ŌURA has a long-standing focus on female well-being
The development represents a step forward in the company’s neuromuscular computing roadmap
The ability to confirm and treat cancer in the same day lets patients get an answer immediately
Radar technology has long played a vital role in aviation and automotive industries
The platform makes it possible to track disease progression and therapy effectiveness in real-time
Analysts see strong upside potential in BeOne’s move into solid tumours
The addition of Induction brings Vitalhub new digital healthcare tools that enhance patient engagement and virtual care
Quest plans to refine, expand, and validate the MCaST technology for its own lab-developed test
Ottawa and Calgary are new participants this year
Chen and colleagues analyzed data from 7,000 adults who contributed Fitbit smartwatch data to the All of Us research program
The test combines mass spectrometry with AI to quickly detect silicosis from breath samples
Western foods are a catalyst for the disease, University of Florida researchers have highlighted
Their study found that leaf and stem extracts from the 'Carolina Ruby' sweet potato are particularly beneficial for fighting lung cancer
The team’s work has been published in the journal Advanced Science
The test operates on the principle that cancers shed DNA into the bloodstream
The data also noted that 23 per cent of Canadians diagnosed with cancer
Pollution appears to be the primary culprit for the phenomenon
MASH is a more severe form of metabolic dysfunction-associated steatotic liver disease formerly known as non-alcoholic fatty liver disease